Please login to the form below

Not currently logged in

Amgen launches bowel cancer web portal in Spain

Aims to help healthcare professionals understand about personalised medicine
amgen canal colon website

Amgen has launched an online portal to support healthcare professionals in Spain whose work involves bowel cancer.

The website,, is focused on metastatic colorectal cancer (mCRC) and content is aimed at all specialists involved in the diagnosis, treatment and monitoring of patients with mCRC.

It is intended to improve clinical practice and to educate healthcare professionals about the potential for personalised medicines in the area.

The portal gives oncologists in Spain access to a range of information, from results of clinical studies to news and events related to mCRC. In sections such as 'Ask the Expert', opinion leaders answer questions about the condition.

Users can also access or register with the platform, which can help them to detect RAS mutations.

Part of the reason for the portal is the continuing rise of personalised medicines for specific types of cancer that are related to gene mutations.

Of particular concern for Amgen in this area is its drug Vectibix (panitumumab), which is approved to treat mCRC patents whose tumour cells contain non mutated (wild-type) 'RAS'.

29th July 2014

From: Marketing



Featured jobs

Subscribe to our email news alerts


Add my company

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...